Curis to Release Second Quarter 2017 Financial Results and Hold Conference Call on August 3, 2017
July 26 2017 - 7:00AM
Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the
development and commercialization of innovative drug candidates for
the treatment of human cancers, today announced that the Company
will release its second quarter 2017 financial results on
Thursday, August 3, 2017, before the U.S. financial markets open.
The Company's management will also host a conference call on the
same day at 8:30 a.m. EDT.
To access the live conference call, please dial (877) 868-1829
from the United States or (253) 237-1135 from other locations,
shortly before 8:30 a.m. EDT. The conference ID number is 61970970.
The conference call can also be accessed on the Curis website at
www.curis.com in the Investors section.
About Curis, Inc.
Curis is a biotechnology company focused on the development and
commercialization of innovative and effective drug candidates for
the treatment of human cancers, including its lead development
candidate, CUDC-907, which is being investigated in clinical
studies in patients with lymphomas and solid tumors. Curis is also
engaged in a broad collaboration with Aurigene in the areas of
immuno-oncology and precision oncology. As part of this
collaboration, Curis has exclusive licenses to oral small molecule
antagonists of the PD1 and VISTA pathways, including PDL1/VISTA
antagonist CA-170, and oral small molecule antagonists of the PD1
and TIM3 pathways, including PDL1/TIM3 antagonist CA-327, as well
as to molecules designed to inhibit the IRAK4 kinase, including
CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial
in patients with advanced solid tumors and lymphomas. Curis is also
party to a collaboration with Genentech, a member of the Roche
Group, under which Genentech and Roche are commercializing
Erivedge® for the treatment of advanced basal cell carcinoma, and
are further developing Erivedge in other diseases including
idiopathic pulmonary fibrosis and myelofibrosis. For more
information, visit Curis's website at www.curis.com.
For More Information:
James E. Dentzer
Chief Financial Officer & Chief Administrative Officer
Curis, Inc.
617-503-6500
jdentzer@curis.com
Media Contact:
David Schull
Russo Partners
212-845-4271
david.schull@russopartnersllc.com
Curis (NASDAQ:CRIS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Curis (NASDAQ:CRIS)
Historical Stock Chart
From Sep 2023 to Sep 2024